Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stimcell EnergeticsSTME 25 Cyclically Adjusted PS Ratio is 7.59 as of Sep. 15, 2026, which is 87% below its 10-year median of 60.00. GuruFocus rates STME with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 529 Medical Devices & Instruments companies, Stimcell Energetics ranks worse than 189035.73% on this metric.
The historical rank and industry rank for Stimcell Energetics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Stimcell Energetics's highest Cyclically Adjusted PS Ratio was 92.25. The lowest was 42.75. And the median was 60.00.
STME's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.22 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Stimcell Energetics's adjusted revenue per share data for the three months ended in May. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.03 for the trailing ten years ended in May. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Stimcell Energetics (OTCPK:STME) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Stimcell Energetics Cyclically Adjusted PS Ratio Related Terms
Stimcell Energetics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Stimcell Energetics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stimcell Energetics Cyclically Adjusted PS Ratio Chart
STME vs AMIX, ITOC, USAQ: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Stimcell Energetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stimcell Energetics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stimcell Energetics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Stimcell Energetics's Cyclically Adjusted PS Ratio falls into.
Stimcell Energetics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Stimcell Energetics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 7.59 mean?
Stimcell Energetics (STME) has a Cyclically Adjusted PS Ratio of 7.59 as of Sep. 15, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stimcell Energetics and its competitors. This is 87% below median its historical median of 60.00. Over the past decade, Stimcell Energetics' Cyclically Adjusted PS Ratio has ranged from 42.75 to 92.25. According to the industry distribution chart, Stimcell Energetics ranks #999999 out of 529 companies in the Medical Devices & Instruments industry.
Is Stimcell Energetics' Cyclically Adjusted PS Ratio too high?
Stimcell Energetics' current Cyclically Adjusted PS Ratio of 7.59 is 87% below median its 10-year median of 60.00. Over the past 10 years, this metric has ranged from a low of 42.75 to a high of 92.25. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.22. Stimcell Energetics' value of 7.59 is 241.9% above this industry median. Based on the distribution chart, Stimcell Energetics ranks #999999 out of 529 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stimcell Energetics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Stimcell Energetics' Cyclically Adjusted PS Ratio compare to AMIX and ITOC?
According to the Medical Devices & Instruments industry distribution chart, Stimcell Energetics ranks #999999 out of 529 companies for Cyclically Adjusted PS Ratio. This places Stimcell Energetics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.22. Stimcell Energetics' value of 7.59 is 241.9% above this benchmark. Historically, Stimcell Energetics' own Cyclically Adjusted PS Ratio has ranged from 42.75 to 92.25 over the past decade. While the company's 10-year median is 60.00 vs. the industry median of 2.22, Stimcell Energetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.22, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stimcell Energetics's current Cyclically Adjusted PS Ratio of 7.59 is 241.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Stimcell Energetics and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stimcell Energetics's current Cyclically Adjusted PS Ratio is 7.59, which is 87% below median its own 10-year median of 60.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stimcell Energetics stock overvalued right now?
Stimcell Energetics (STME) has a current Cyclically Adjusted PS Ratio of 7.59. The current Cyclically Adjusted PS Ratio is 7.59, which is 87% below median its 10-year median of 60.00 and 241.9% above the Medical Devices & Instruments industry median of 2.22. Stimcell Energetics' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Stimcell Energetics (STME), the current Cyclically Adjusted PS Ratio is 7.59 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stimcell Energetics Inc is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness, and alleviate health complications, including, but not limited to: aging, diabetes, high blood pressure, neuropathy, and kidney function. The company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System.
25GF Score
Get the complete analysis for STME
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STME has been successfully added to your 
